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The peroxisome proliferator-activated receptor (PPAR) g regulates the expression of genes involved in
adipogenesis, lipid homeostasis, and glucose metabolism, making it a valuable drug target. However, full
activation of the nuclear receptor is associated with unwanted side effects. Research therefore focuses on
the discovery of novel partial agonists, which show a distinct protein-ligand interaction pattern
compared to full agonists. Within this study, we employed pharmacophore- and shape-based virtual
screening and docking independently and in parallel for the identiﬁcation of novel PPARg ligands. The
ten top-ranked hits retrieved with every method were further investigated with external in silico
bioactivity proﬁling tools. Subsequent biological testing not only conﬁrmed the binding of nine out of the
29 selected test compounds, but enabled the direct comparison of the method performances in a pro-
spective manner. Although all three methods successfully identiﬁed novel ligands, they varied in the
numbers of active compounds ranked among the top-ten in the virtual hit list. In addition, these com-
pounds were in most cases exclusively predicted as active by the method which initially identiﬁed them.
This suggests, that the applied programs and methods are highly complementary and cover a distinct
chemical space of PPARg ligands. Further analyses revealed that eight out of the nine active molecules
represent novel chemical scaffolds for PPARg, which can serve as promising starting points for further
chemical optimization. In addition, two novel compounds, identiﬁed with docking, proved to be partial
agonists in the experimental testing.
© 2016 The Author(s). Published by Elsevier Masson SAS. This is an open access article under the CC BY
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The peroxisome proliferator-activated receptors (PPARs) belong
to the class of nuclear receptors. Upon activation, the receptor
forms heterodimers with the retinoid X receptor (RXR) to control
the expression of its targets genes [1]. PPARg is highly expressed in
adipose tissue [2], where it is involved in adipogenesis [3], lipid
homeostasis, and glucose metabolism (reviewed in Ref. [4]). It gets
activated by a variety of endogenous compounds such as eicosanoid
15-deoxy-D12,14-prostaglandin J2 or the fatty acid arachidonic acid
[5], and by a number of synthetic [6e11] and natural compounds
[12]. Most prominently, PPARg was identiﬁed as the molecular
target of the thiazolidinedione (TZD) class of antidiabetic drugs
[7,8], including the blockbuster drugs rosiglitazone and pioglita-
zone. TZDs, of which most are full agonists, promote increased in-
sulin sensitivity. However, their administration has also beencess article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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congestive heart disease [13]. These deleterious effects were found
to be diminished whereas beneﬁcial effects on insulin sensitivity
were maintained, when PPARg was only partially activated [6,14].
The design of several partial agonists of PPARg with improved side
effect proﬁles have been reported [11,15,16], including the selective
angiotensin receptor blocker telmisartan [9] and its analogues [17].
Partial agonists were shown to display a different interaction mode
in the ligand-binding domain compared to full agonists. Most
prominently, other than full agonists, partial agonists do not sta-
bilize helix H12 via hydrogen bonding with Tyr473 [18].
Virtual screening tools are nowadays well integrated in the drug
development process to complement and support experimental
high-throughput screenings in the selection of the most promising
drug candidates [19]. Several different virtual screening methods
are available for this purpose [20] (please refer to www.click2drug.
org for a comprehensive list of virtual screening tools), and many of
them have already been successfully applied for the identiﬁcation
of novel PPARg ligands [21e28]. However, whether there are dif-
ferences in their performances, and if so, which one is the most
suitable for addressing nuclear receptor-related issues, and PPAR-
related in particular, is still unclear. Several method comparisons
have been published throughout the last years [29e38], which
points out the raising interest in this topic. Unfortunately, the
different methodical set-ups of these studies hamper their com-
parison on a larger scale. Therefore, a comprehensive and pro-
spective evaluation of the same methods employing identical
datasets still remains to be accomplished.
We have already investigated the performances of selected
common virtual screening tools for the identiﬁcation of novel
bioactive molecules for cyclooxygenases-1 and -2 as representa-
tives of classical enzymes [39], and for members of the cytochrome
P450 (CYP) superfamily involved in metabolic turnover [40].
Intriguingly, we could observe quite distinct performances of the
tools, suggesting that different tools might be better suited to meet
the requirements of the various target classes. Nuclear receptors
display different properties concerning the structure of the proteins
and the ligands compared to the two examples investigated so far,
which might be attributed to their different biological functions.
Therefore we assumed that our ﬁndings so far may not be extrap-
olated to nuclear receptors. To investigate the advantages and
limits of selected common virtual screening tools also for this target
class, we selected PPARg as a case study representing nuclear re-
ceptors and applied the same study design in linewith our previous
investigations [39]. As mentioned above, research efforts con-
cerning PPARg shifted towards the identiﬁcation of partial agonists
rather than full agonists. Besides the identiﬁcation of the most
suitable virtual screening method for the identiﬁcation of novel
PPARg ligands, we therefore additionally aimed to investigate the
ability of the applied methods to reﬂect this speciﬁc binding mode
that results in the partial activation of the receptor.
2. Methods
2.1. Study design
Analogous to our previous study [39], we generated PPARg
partial agonist pharmacophore- and shape-based models, and
established a docking protocol that could discriminate between
PPARg partial agonists, PPARg full agonists, and inactive com-
pounds. All optimized models and the docking workﬂowwere used
for virtual screening of the commercial Maybridge database (www.
maybridge.com). The ten top-ranked hits from each of the three
methods were selected for further investigations andmerged to the
“overall hit list”. In the next step, we analyzed whether thesecompounds were also predicted by the other two virtual screening
methods above the activity cut-off deﬁned during the model gen-
eration and theoretical validation. In addition, all compounds were
independently and in parallel investigated with external 2D- and
3D bioactivity proﬁling tools. All generated in silico predictions
were summarized in a prediction matrix. After biological testing,
the performances of all the applied tools were evaluated and
compared. The workﬂow is depicted in Fig. 1.
2.2. Hardware speciﬁcation
All processes and predictions were performed on a multi-core
workstation with 2.4 þ GHz, 8 GB of RAM, a 1 þ TB fast mass
storage, and a NVIDIA graphical processing unit. All programs run
on the Windows 7 platform.
2.3. Datasets
Known active partial agonists of PPARg were manually assem-
bled from the literature. Only compounds that activated the re-
ceptor from 15% up to a maximum of 80% compared to the full
agonist control in a transactivation assay, and where direct binding
was either shown by scintillation proximity assay or crystallo-
graphic datawere included. In total, 51 knownpartial agonists were
included in the “partial agonist” dataset (a detailed list is provided
in Table S1 of the supporting information).
To investigate whether the generated models and the docking
workﬂow can discriminate between full and partial agonists, also a
“full agonist” dataset was included. This dataset contained 14
known full agonists from the literature for which direct binding
was shown either via X-ray crystallography or a scintillation
proximity assay and that activated the receptor >80% in a trans-
activation assay (for a detailed list of compounds please refer to
Table S2 of the supporting information). Some of these compounds
originated from the same chemical series as known partial agonists
and were therefore especially useful for investigating the structural
characteristics determining the biological activity.
PPARg was included as target in the ToxCast dataset and eval-
uated in a ﬂuorescence polarization assay [41]. The CAS-numbers of
all compounds that were inactive in this dataset against PPARg
were extracted and converted to a sd-ﬁle using Pipeline Pilot
version 9.1 [42] script “Search PubChem for CAS Number”. Thereby,
a database of 799 unique structures (Table S3 in the supporting
information) was generated. A detailed description of this protocol
is provided in Fig. S1 of the supporting information. In addition, 13
compounds which proved to be inactive in in vitro binding assays
were manually assembled from the literature (a detailed list is
provided in Table S4 of the supporting information). In total, this
led to an “inactives” dataset containing 812 known inactive
compounds.
A cdx-ﬁle was created for all literature-derived compounds us-
ing ChemBioDraw Ultra 11.0 [43]. These cdx-ﬁles were then con-
verted to sd-ﬁles using the ChemDraw Reader and SD Writer
components in Pipeline Pilot 8.5 [44].
For the prospective screening, the Maybridge_HitDiscover
database was downloaded from the Maybridge homepage (www.
maybridge.com, access date 27 February 2014). This compound
collection contained about 52,000 diverse molecules that are
commercially available. According to the information on the
homepage of the provider, the majority of compounds does fulﬁll
generally acknowledged criteria of drug-likeness (http://www.
maybridge.com/portal/alias__Rainbow/lang__en/tabID__146/
DesktopDefault.aspx). As a consequence, we did not apply addi-
tional pre-screening ﬁlters, which would have introduced addi-
tional bias to this study: The application of an additional ﬁlter
Fig. 1. Study design.
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accordingly change the compounds selected for testing. Therefore,
the performance of the virtual screening tools would depend not
only on the intrinsic properties of the method, but also on the
calculated ADMET properties of the screening database.
In principle, multiple commercially available compound col-
lections can be employed for virtual screening. The composition of
these databases may, however, also have an impact on the results.
We therefore applied just one unmodiﬁed screening database to
allow for the comparison of the methods performances without
any inﬂuence of the data set and its predicted pharmacokinetic
properties.2.4. Prospective virtual screening tools
Analogous to our previous studies [39,40], LigandScout 3.1 [45]
was employed for pharmacophore-based screening, vROCS 3.0.0
[29,46] for shape-based screening, and GOLD [47,48] version 5.2
was applied for all docking studies. A detailed description of the
programs and the virtual screening parameters is provided in
Section S1 of the supporting information. The virtual hits retrieved
from prospective screening were ranked according to the respec-
tive ﬁtness scores and the top-ranked molecules were selected for
biological testing. Whenever close analogues were ranked in the
top-ten, the one with the lower score was discarded and the next-
ranked molecule was selected. Also compounds with reduced sta-
bility such as esters were discarded.2.5. External proﬁling tools
Several commercial and open source bioactivity proﬁling tools
are available and analogous to our previous studies [39,40] we also
investigated whether these tools can correctly predict the activity
of selected compounds with regard to a speciﬁc target. In detail,
predictions were generated with the 2D similarity-based programs
SEA [49] and PASS [50] and the pharmacophore-based proﬁling
tools PharmMapper [51]. These tools are readily available online
and may be very valuable because of their simple and fast appli-
cation. A detailed description of these tools is provided in Section
S2 of the supporting information.2.6. Biological testing
Pioglitazone and telmisartan were extracted as previously
described [17]. The identity and purity of both compounds was
conﬁrmed via 1H-NMR prior to their usage. Identity and purity data
of the commercial test compounds were provided by Maybridge.
Compounds were re-analyzed via HPLC whenever data were
missing. Detailed information regarding HPLC analyses is provided
in Section S3 in the supporting information. For all active com-
pounds, the identity and a purity of 95% was conﬁrmed.2.7. Time-resolved ﬂuorescence resonance energy transfer (FRET)
in vitro
A cell-free LanthaScreen TR-FRET PPARg competitive binding
assay kit [52] (Life Technologies, Darmstadt, Germany) was used
according to the manufacturer's protocol. Brieﬂy, the human re-
combinant ligand binding domain of PPARg is tagged with glu-
thatione S-transferase (GST) and can be recognized by a terbium-
labelled anti-GST antibody. Dilution series of the tested com-
pounds in the indicated concentrations were produced in tripli-
cates and incubated with the PPARg-LBD, the anti-GST antibody,
and Fluoromone™ (5 nM), a ﬂuorescein-labelled pan-PPAR agonist.
The maximum concentration of pioglitazone and telmisartan rep-
resented the positive assay controls and DMSO (FLUKA, Buchs,
Switzerland) served as the negative control. Binding of the
ﬂuorescein-labelled agonist and thus resulting close proximity of
terbium and ﬂuorescein increased the FRET signal, competitive
displacement of the ﬂuorescein-labelled agonist by tested com-
pounds decreased the FRET signal. In case of autoﬂuorescence of
the tested compound, the ﬂuorescence intensity of compound at
the given concentration was measured as blank and subtracted
from the TR-FRET signal. Fluorescence intensities were measured
with a ﬁlter-based Enspire plate reader (Perkin Elmer) and the FRET
signal was calculated by the ratio of the emission signal at 520 nm
(ﬂuorescein) and 495 nm (terbium), respectively. Instrument set-
tings were conform to the suggestions of the manufacturer of
LanthaScreen assays and were veriﬁed with a LanthaScreen Tb in-
strument control kit (Life Technologies, Darmstadt, Germany).
All compounds that showed at least 40% of the activity of the
positive control pioglitazone were considered as active.
Concentration-response curves were determined for the most
active molecules, which showed at least 60% of the pioglitazone
activity.2.8. Transactivation assay
The transactivation assaywas conducted as described elsewhere
[17]. COS-7 cells (AATC) were seeded in 96-well plates at a density
of 104 cells/well in Dulbecco's Modiﬁed Eagle Medium (DMEM)
with 4,5 g/L glucose, 584mg/L L-glutamine, supplementedwith 10%
FCS (Biochrom, Berlin, Germany) and 1% penicillin/streptomycin
(Life Technologies, Darmstadt, Germany), and incubated at 37 C
and 5% CO2 for 24 h prior to transfection. After changing to serum-
and antibiotic-free medium, cells were transiently transfected with
pGal5-TK-Luc (30 ng), pGal4-PPARg-LBD (3 ng) and pRenilla-CMV
(1 ng) in OptiMEM (25 mL; Gibco, Darmstadt, Germany). After 4 h,
the selected compounds, pioglitazone, or vehicle (DMSO from
FLUKA, Buchs, Switzerland) were added at indicated concentra-
tions, and luciferase activity was measured after 42 h. Transient
transfection (Lipofectamin 2000; Life Technologies, Darmstadt,
Germany) and dual-luciferase reporter assay (Promega, Germany)
were performed according to the manufacturer's protocol.
All compounds, the controls pioglitazone and telmisartan, and
DMSO were tested in triplicates at a concentration of 10 mM in a
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percent activation compared to the control pioglitazone and the %
standard deviation (SD) were calculated. For compounds with a
mean e SD higher than the mean of the DMSO control þ SD (12.1%
receptor activation at 10 mM), the EC50 value and the maximum % of
receptor activation compared to pioglitazone were determined.2.9. Analysis of the results
During the theoretical validation, the enrichment factor (EF)
[53] was calculated according to Equation (1):
EF ¼ TP=n
A=N
(1)
In this equation, TP represents the number of true positives (i.e.
active virtual hits), n the number of all virtual hits, A the number of
all active molecules in the validation dataset, and N the number of
all compounds in the validation dataset. This metric, however, is
highly dependent on the relation of active and inactivemolecules in
the dataset. To provide more independent quality metrics, we
normalized the EF to themaximum (max) EF and calculated the % of
the maxEF a model yielded. In addition, the area under the curve
(AUC) of the receiver operating characteristic (ROC)-plot was
calculated as described by Triballeau et al. [54].
After the biological testing, the performances of the prospective
virtual screening tools were analyzed in three categories.
In the ﬁrst category, early enrichment (EE), we investigated,
which percentage of the top-ten ranked compounds was active in
the biological testing (Equation (2)).
EE ¼ number of active compounds in the top 10 hit list
10
100
(2)
This quality metric was only calculated for the three methods
pharmacophore modeling, shape-based modeling, and docking,
because the external proﬁling tools do not allow for virtual
screening of large compound databases. Using these tools, one
compound after the other has to be proﬁled, which prohibits the
investigation of large compound libraries as accomplished with the
other three methods. All other quality parameters described below
were also calculated for the bioactivity proﬁling tools.
In the second category, overall enrichment (OE, Equation (3)),
we investigated whether the compounds were also predicted by
the other methods above the activity-cut-off. For ROCS and dock-
ing, the activity cut-offs were deﬁned during the theoretical vali-
dation. For SEA, a cut-off of E-value  4 was selected, as proposed
by Lounkine et al. [55]. For PASS, a cut-off of Pa  0.5 was applied,
because most of the active compounds were proven to be distrib-
uted above this value [56].
OE¼ number of predicted and active compounds
number of predicted compounds from themerged hit list
100
(3)
In the last category, we analyzed how many of the predictions
were correct. A prediction was considered as correct, when a
compound was predicted to be active and indeed was active in the
biological assay, but also when a compoundwas not predicted to be
active and was inactive in the experimental testing. We refer to this
value as accuracy (Acc [57], Equation (4)). For this purpose, the
number of TP, false positive (percentage of predicted but biologi-
cally inactive compounds, FP), true negative (percentage of com-
pounds that were not predicted and indeed were inactive in the
biological testing, TN), and false negative (number of compoundsthat were not predicted, but were active in the biological testing,
FN) hits was calculated.
Acc ¼ TP þ TN
TP þ FP þ TN þ FN*100 (4)
Since the TP, TN, FP, and FN rates heavily depend on the actual
composition of active and inactive molecules in the overall hit list,
these values were also normalized. For example, the normalized TP
rate was calculated as the percentage of the maxTP rate retrieved.
For the maxTP rate, the number of actual active hits was divided
through the number of overall compounds in the overall hit list. The
maxTN, maxFP, and maxFN rates were calculated alike. These
values are provided in addition to better assess the performances of
the applied methods.3. Results
3.1. Pharmacophore modeling
In total, 10 models using ﬁve PDB entries (2Q5S [18], 3H0A [58],
2Q5P [18], 3FUR [11], and 3QT0 [59]), and one additional ligand-
based model were generated with LigandScout 3.1 [45]. For the
prospective part, however, three optimized models were selected,
because they performed very well in the theoretical validation and
together found the majority of compounds in the “partial agonist”
dataset.
The ﬁrst selected model was generated with the crystal struc-
ture of PPARg in complex with the partial agonist nTZDpa (PDB-
entry 2Q5S [18]). The reﬁned model pm-2q5s (Fig. 2A) mapped 37
out of the 51 (72.5%) partial agonists in the dataset, 64 inactive
compounds out of 812 (7.9% of the dataset), but no full agonist. It
therefore retrieved an EF of 6.2, representing 37% of the maxEF.
The second model was based on the crystal structure of tetra-
hydronaphthalene derivative 1 (Fig. 3) in complex with PPARg
(PDB-entry 3H0A [58]). The optimized model pm-3h0a (Fig. 2B)
matched only 9 out of 51 (17.6%) partial agonists, but also only 7 out
of 812 (0.9%) inactive compounds in addition to one out of 14 full
agonists (7.1%). It yielded an EF of 9.0 (53% of the maxEF).
The last model selected for the prospective screening was a
ligand-basedmodel generated with the known partial agonists GQ-
16 2 [15] and PA-082 3 [60] (Fig. 3). For these two molecules, Ki
values of 0.16 mM [15] and 0.8 mM [60] were determined, and they
activated the receptor up to approximately one third [15] and 40%
[60] compared to the full agonist rosiglitazone, respectively. The
ﬁnalized pharmacophore model, pm-PPARg-pAg (Fig. 2C), found 9
out of the 51 (17.6%) partial agonists and 7 out of the 812 (0.9%)
inactive compounds. It did not map any full agonist of the dataset.
This led to an EF of 9.5, which represents 56% of the maxEF.
In combination, all three models covered 48 out of the 51 partial
agonists (94.1%), but only retrieved one out of the 14 full agonists
(7.1%) and 74 out of the 812 (9.1%) inactive molecules. Together,
they yielded an EF of 6.5, corresponding to 38% of the maxEF.
Finally, they retrieved an AUC of 0.92.
In the prospective screening of the commercial Maybridge
database (52,000 entries), 9231 unique compounds mapped at
least one of the models. In detail, model pm-2q5s mapped 7393
molecules, model pm-3h0a retrieved 177 virtual hits, and model
pm-PPARg-pAg matched 2369 compounds. All virtual hits were
ranked according to their relative geometric pharmacophore ﬁt
score, and the top ten ranked diverse and chemically stable mole-
cules were selected for biological testing. A detailed list of the
selected compounds and their highest relative Fit values is pro-
vided in Table 1.
Fig. 2. Pharmacophore models for PPARg partial agonists. (A) Model pm-2q5s was based on the PDB-entry 2Q5S [18]. It consisted of 4 hydrophobic (H) features, 2 hydrogen bond
acceptors (HBAs) to Ser342 and, water-mediated, to Arg288 and Glu343. Tyr473 of helix H12 is not involved in the binding and far away. (B) Model pm-3h0a was created using the
PDB-entry 3H0A [58]. It contained three Hs, one negatively ionizable feature (NI), and one HBA. The latter two represented the interaction with Arg288. In addition, the model
contained four optional HBAs. Partial agonists do not have to match these features, but they were crucial for proper feature alignment in LigandScout during virtual screening. (C)
Model pm-PPARg-pAg was generated with the two known partial agonists GQ-16 2 (gray) and PA-082 3 (blue). It consisted of 2 H, two HBAs, and one aromatic ring (Ar) feature.
Yellow spheres, H; red arrows and red spheres, HBAs; blue ring, Ar feature. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web
version of this article.)
Fig. 3. Structures of the training set compounds tetrahydronaphthalene derivative 1, GQ-16 2, PA-082 3, and isoxazolone derivative 4 [61].
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In the course of shape-based modeling, a total number of 50
models was generated with vROCS 3.0.0 [29,46]; however, similar
to pharmacophore modeling, only a selection of the best-
performing models during the theoretical validation was applied
for the prospective part.
The co-crystallized ligands of PPARg-compound complexes
served as query molecules for four shape-based models. These li-
gands were preferentially selected for model generation, because
they represent the biologically relevant conformations. Neverthe-
less, also one model based on one low-energy conformation of the
known partial agonist isoxazolone derivative 4 [61] (Fig. 3) was
used for the successful retrieval of most of the compounds in the
“partial agonist” dataset. The ﬁnal shape-based models and their
performances in the theoretical validation are summarized in
Table 2. These models are depicted in Fig. 4AeE.
All models combined covered 35 out of the 51 (68.6%) partial
agonists, but only mapped two out of 14 (14.3%) full agonists and 17out of 812 (2.1%) known inactive molecules. Together, they yielded
an EF of 11.0%, representing 65% of the maxEF, and an AUC of 0.83.
In the prospective screening, 1848 unique compounds mapped
at least one ROCS-model above the deﬁned activity cut-off. A
detailed list of the number of virtual hits per model is provided in
Table 2. For all virtual hits, the relative ComboScore was calculated
manually as described in Section S1 in the supporting information,
and this score was subsequently used to rank all mapping com-
pounds. The ten top-ranked diverse and stable compounds were
selected for further in silico and experimental investigations. For a
detailed list of selected compounds and their relative ComboScores
please refer to Table 1.3.3. Docking
In total, docking workﬂows were generated with GOLD [47,48]
version 5.2 using the eight crystal structures 2Q5S [18], 2Q5P
[18], 2Q6S [18], 2YFE [62], 3FUR [11], 3V9Y [63], 4A4V [64], and
4A4W [64]. Finally, we selected only the best-performing docking
Table 1
Prediction matrix for overall hit list. Values obtained in the top-ten hit lists of the respective methods are highlighted in bold.
Name LigandScouta ROCSb GOLDc SEAd PASSe PharmMapperf Activitym
Top-ranked pharmacophore modeling hits Compound 5 0.97h e e e e e e
Compound 6g 0.97h 1.215j e e e e e
Compound 7 0.97h e e e e e e
Compound 8 0.96h e e e e e e
Compound 9 0.96h e e e e e þ
Compound 10 0.96h e e e e e þ
Compound 11 0.96h e e e e e e
Compound 12 0.96h e e e e e þ
Compound 13 0.96h e e e e e e
Compound 14 0.95i e e e e e e
Top-ranked shape-based modeling hits Compound 15 e 1.265k e e e 0.607 þ
Compound 16 e 1.254j e e e e e
Compound 17 e 1.251j e e e e e
Compound 18 e 1.233l e e e e þ
Compound 19 0.93h 1.217l e e e e e
Compound 20 e 1.198j e e e e e
Compound 21 e 1.196l e e e e e
Compound 22 0.93h 1.192j 127.019 e e e e
Compound 23 e 1.189k e e e e e
Top-ranked docking hits Compound 24 e e 146.089 9.93e-4 e e þ
Compound 25 e e 144.178 e e 0.634 e
Compound 26 e e 141.653 e e e þ
Compound 27 e e 141.154 e e e e
Compound 28 e 1.011l 140.461 e e e e
Compound 29 e e 139.719 e e e þ
Compound 30 0.93h e 139.554 e e e e
Compound 31 e e 138.331 e e e e
Compound 32 e e 37.578 e e e þ
Compound 33 e e 136.966 e e e e
a Only highest relative pharmacophore ﬁt score is listed for every compound, high values are desirable.
b Only highest relative ComboScore is listed for every compound, high values are desirable.
c Only highest GoldScore is listed for every compound, high values are desirable.
d Only lowest E-value below the activity cut-off is listed for every compound, low values are desirable.
e Only Pa values above activity cut-off are listed, high values are desirable.
f Highest relative pharmacophore ﬁt score retrieved with a model with at least 6 features, high values are desirable.
g Consensus hit ranked in the top-ten of both the pharmacophore- and shape-based modeling hit list.
h Identiﬁed with model pm-2q5s.
i Identiﬁed with model pm-3h0a.
j Identiﬁed with model shape-2q5s.
k Identiﬁed with model shape-3vn2.
l Identiﬁed with model shape-3fur.
m þ active in the biological testing, - inactive in the biological testing.
Table 2
Shape-based models applied in this study.
Model Source ComboScore
cut-off
No. of mapping partial
agonists (%)
No. of mapping full
agonists (%)
No. of mapping
inactives (%)
EF (%
maxEF)
Hits in the prospective
screening
Shape-2q5s 2Q5S [18] 1.20 14 out of 51 (27.5%) 1 out of 14 (7.1%) 5 out of 812 (0.6%) 11.8
(70%)
423
Shape-2q5p 2Q5P [18] 0.94 15 out of 51 (29.4%) 1 out of 14 (7.1%) 3 out of 812 (0.4%) 13.4
(79%)
247
Shape-3fur 3FUR [11] 1.20 5 out of 51 (9.8%) 0 out of 14 (0%) 4 out of 812 (0.5%) 9.4 (56%) 419
Shape-3vn2 3VN2 [9] 0.88 9 out of 51 (17.6%) 1 out of 14 (7.1%) 7 out of 812 (0.9%) 9.0 (53%) 754
Shape-
PPARg-pAg
isoxazolone derivative
4 [61]
1.04 6 out of the 51 (11.8%) 0 out of 14 (0%) 0 out of 812 (0%) 16.9
(100%)
81
Fig. 4. Shape-based models for PPARg partial agonists. The models were generated with (A) nTZDpa (PDB-entry 2Q5S [18]), (B) MRL24 (PDB-entry 2Q5P [18]), (C) INT131 (PDB-entry
3FUR [11]), (D) telmisartan (PDB-entry 3VN2 [9]), and (E) one low-energy conformation of the known partial agonist isoxazolone derivative 4 [61]. Color features were added to
reﬁne the shape models: green sphere, ring feature; red sphere, anion; blue sphere, cation; yellow sphere, hydrophobic; red mesh, HBA. (For interpretation of the references to
colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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limit the time required for the docking of the about 52,000 mole-
cules in the Maybridge database. The crystal structure of PPARg in
complex with the partial agonist amorfrutin B (PDB-entry 4A4W
[64]) was employed for docking, because 18 out of the 51 (35.3%)
partial agonists, but only 2 out of 14 (14.3%) full agonists and 4 out
of 84 (4.8%) inactive compounds from the reduced “inactives”
dataset for docking were scored above a GoldScore of 124.0. Since
this GoldScore allowed for a good balance between the retrieval of
partial agonists while excluding full agonists and inactive com-
pounds, respectively, it was selected as activity cut-off. Thereby,
docking yielded an EF of 2.2, representing 75% of the maxEF, and an
AUC of 0.65. However, this comparably low AUC is rather due to the
strict activity cut-off selected, which consequently leads to a
smaller portion of partial agonists ranked above this value, than to a
large number of full agonists or inactive compounds predicted to be
active.
In the prospective docking run, 809 unique compounds were
docked into the binding site of PPARg with a GoldScore of 124.0.
All virtual hits were ranked according to the GoldScore and the top-
ten ranked diverse and chemically stable molecules were selected
for further investigations. For a detailed list of selected compounds
and their GoldScore, please refer to Table 1.
3.4. Generation of a prediction matrix
The top-ten ranked diverse and stable compounds retrieved
with the three methods pharmacophore modeling, shape-based
modeling, and docking were merged to an overall hit list. One
compound, compound 6, was ranked among the top-ten molecules
by both pharmacophore- and shape-based modeling. Therefore,
the overall hit list contained 29 unique compounds. In the next
step, it was investigated whether these compounds were also
predicted by the other two methods above the deﬁned activity cut-
off in case they were not ranked among the top-ten. In addition, all
compounds were further proﬁled with the external bioactivity
proﬁling tools SEA, PASS, and PharmMapper (see below). All pre-
dictions for every compound were then collected in a prediction
matrix (Table 1).
3.5. External proﬁling tools
All 29 compounds from the overall hit list were further inves-
tigated with the external bioactivity proﬁling tools SEA [49], PASS
[50], and PharmMapper [51]. SEA predicted one compound, com-
pound 24, above the activity cut-off, while PASS did not calculate a
Pa value of0.5 for a single compound. When using PharmMapper,
two compounds, 15 and 25, mapped a PPARg pharmacophore
model consisting of at least six features. All predictions generated
with the three external bioactivity proﬁling tools for every com-
pound were added to the prediction matrix (Table 1).
3.6. Biological results
In the TR FRET assay, displacement of the labelled ligand was
observed for nine out of the 29 investigated compounds (Table 3
and Fig. 5). These compounds therefore proved to bind to PPARg.
For the ﬁve most active compounds, which showed at least 60% of
the binding of pioglitazone, concentration-response curves were
determined (Fig. 6). Compounds 10, 26, and 32 showed a sigmoidal
curve and a maximum ligand displacement of 50, 60, and 80%,
respectively. For compound 26, a similar concentration-response
curve as the positive control pioglitazone was observed, proving
that they have equal afﬁnity towards PPARg (Fig. 6A). The two
remaining active compounds 15 and 24 showed linearconcentration-response relationships. The partial agonist telmi-
sartan showed a higher afﬁnity than the tested compounds and
pioglitazone (Fig. 6).
To further elucidate the biological effects of the compounds, all
of them were investigated in a transactivation assay. In this assay,
however, only two of the molecules could induce higher gene
expression than the mean ± SD of the DMSO control. These results
may either be caused by the compounds pharmacokinetic proper-
ties (low membrane permeability, low solubility in the cellular
buffer) or the biological activity (compounds are antagonists). The
ﬁrst molecule, compound 24, activated PPARg up to 20.6± 3.9% at a
concentration of 10 mM. Compound 26, the second active com-
pound, activated PPARg up to 29.8± 6.3% at a concentration of
10 mM. For these two compounds, which also were the most active
ones in the FRET assay, and for pioglitazone, concentration-
response curves were also determined in the transactivation
assay. These curves were sigmoidal (Fig. 7) and therefore allowed
for the calculation of EC50 values of 3.4 ± 0.9 mM and 21.7 ± 6.3 mM
for compound 24 and 26, respectively. An EC50 value of 0.5 ± 0.1 mM
and 4.7 ± 0.3 mM was determined for the positive controls piogli-
tazone and telmisartan, respectively. Pioglitazone is a full agonist,
and its maximum receptor activationwas therefore set to 100%. The
two novel compounds 24 and 26 induced a maximum receptor
activation of 23.7 ± 2.2% and 41.9± 2.7% compared to pioglitazone.
Similar to telmisartan, which showed a maximum receptor acti-
vation of 48.2± 3.0% compared to pioglitazone, they activated the
receptor to a lesser extent and proved to be partial agonists in the
transactivation assay. The results of the biological testing for all
active compounds and the positive controls pioglitazone and tel-
misartan are summarized in Table 3.
The structures of the inactive compounds as well as their bio-
logical activity in the experimental testing are provided in Table S5
in the supporting information.
3.7. Analysis of the applied methods
The performances of all applied tools and for every quality
metric, as described in more detail in the Methods Section, are
listed in Table 4. No values for EE are included for the bioactivity
proﬁling tools SEA, PASS, and PharmMapper, because no test
compounds were selected based on predictions generated by them.
A detailed graphical representation of all method performances
including EE, OE, Acc, TP, TN, FP, and FN rates is displayed in Fig. 8.
An analysis of the relative quality metrics maxTP, maxTN, maxFP,
and maxFN is provided in Fig. S2 of the supporting information.
4. Discussion
4.1. Evaluation of the applied programs
The main aim of this study was to evaluate the performances of
commonly used, selected virtual screening tools such as the
pharmacophore-based software LigandScout, the shape-based
modeling program ROCS, and the docking software GOLD. The
terms “program” and “method” were applied exchangeable in this
section, because the selected programs were compared as repre-
sentatives of the different methods. In addition, the ability of the
freely available bioactivity proﬁling tools SEA, PASS, and Pharm-
Mapper to correctly classify the molecular target PPARg for the 29
molecules of interest was investigated. The latter tools are readily
available online andmay thus allow for the fast and straightforward
identiﬁcation of novel targets for the compounds of interest.
Despite the limited scope of this study - only ten molecules per
prospective screeningmethodwere subjected to biological testing -
we could already observe considerable differences in the
Fig. 5. Structures of the active compounds 9, 10, 12, 15, 18, 24, 26, 29, and 32.
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should support the application of the most suitable virtual
screening tool, whenever nuclear receptors are investigated with
computational models in future studies.
Four of the novel PPARg ligands have been identiﬁed with
docking, proving it to be the most successful method in retrieving
active molecules in this study. This result is somewhat unexpected,
as in our previous studies, docking was the method that retrieved
fewer active compounds compared to the other two techniques
(nevertheless, it had other advantages) [39,40]. In addition, two of
the active compounds were ranked on ﬁrst and third place. The
performance of docking is often assumed to suffer from scoring
[65], i.e. the correct ranking of compounds based on their actual
activity, and also we had observed, that all of the compounds that
were correctly classiﬁed by docking in our previous studies were
not ranked in the top-two positions [39,40]. However, this study on
PPARg ligands provides an example proving that prospective
docking and scoring can be very successful if the scoring function is
appropriate for the target. In our recent study on CYP metabolic
enzymes, no theoretically validated docking workﬂows could be
generated for CYP2C9 and 3A4 [40]. We suggested that this ﬁnding
is due to the larger binding pockets of these two targets (~470 Å3
and up to 2000 Å3 for CYP2C9 [66] and 3A4 [67], respectively),
which offer more possibilities to incorrectly ﬁt inactive compounds
into the binding pocket and retrieve high-scoring poses [40].
However, the binding pocket of PPARg was estimated ~1300 Å3
[68], which is much larger as e.g. the CYP2C9 binding site. In
contrast to the CYP enzymes, where the binding pockets are formed
by one large cavity, the PPARg binding site consists of three Y-
shaped narrow channels. This clear separation and the narrowcomposition of the three channels facilitated a precise deﬁnition of
the intended binding site, despite the large size of the overall
binding pocket. These results suggest that not only the size, but also
the overall composition of the binding pocket inﬂuences the
docking performance.
Besides correct ranking and the identiﬁcation of novel bioactive
molecules, docking proved to be highly suitable to distinguish be-
tween full and partial agonists and represent the speciﬁc partial
agonist binding mode. This docking workﬂow may therefore be a
valuable tool for further studies.
The pharmacophore-based virtual screening protocol was suc-
cessful in the identiﬁcation of novel PPARg ligands. The exact ac-
tivity, i.e. whether the compounds display agonistic or antagonistic
activity, could not be determined. Accordingly, we cannot evaluate
whether the pharmacophore models were also successful in dis-
tinguishing between the distinct activity classes. All active com-
pounds were identiﬁed with model pm-2q5s. This model was less
speciﬁc in the theoretical validation, as it also mapped more than
7% of the inactive molecules. Also in the prospective screening, it
retrieved a large proportion of the database compared to the other
models. Nevertheless, it proved a very valuable tool for ranking
active compounds at the top of the hit list and may therefore be
applied also in future PPARg-associated drug discovery projects.
According to the good performance during the theoretical vali-
dation, the ROCS models also performed well in the prospective
virtual screening. Although they did not identify as many novel
active compounds as docking and pharmacophore modeling,
shape-based modeling contributed two novel PPARg ligands to the
overall hit list that would have been missed with the other two
prospective screening techniques. These two molecules,
Fig. 6. Concentration-response curves of compounds 24 and 26 (A) and compounds
10, 15, and 32 (B), and the positive controls pioglitazone and telmisartan (A, B) for the
FRET assay, respectively.
Fig. 7. Concentration-response curves of compounds 24 and 26 and the positive
controls pioglitazone and telmisartan for the transactivation assay.
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different models. In general, if one compares the ﬁve ﬁnal models
(Fig. 4), it is intriguing to observe how diverse they are. The shapes
of model shape-2q5s (Fig. 4A) and shape-3fur (Fig. 4C) are almost
complementary. This suggests that the geometry of the ligandsmay
not be such an important factor in PPARg binding. Nevertheless,
ROCS proved to be successful in the retrieval of active compounds,
and, similar to the other prospective in silico workﬂows developed
in this study, represents a valuable tool for future projects.
In total, nine novel PPARg ligands were identiﬁed in this study.
The most active ones of these compounds bind PPARg in the low
micromolar range (EC50s of 2.1e5.4 mM) in the cell-free assay
similar to the positive control pioglitazone (EC50 of 1.6 mM). For
compound 24, an EC50 of 606 nMwas determined, thereby showing
that this compound has a higher binding afﬁnity than pioglitazone.
Although the remaining compounds are only weakly active, the
identiﬁcation of nine novel active hits conﬁrmed PPARg ligands can
be seen as remarkably successful. Only 29 compounds were tested
at all, thereby leading to a hit rate of 31%. In the context of virtual hit
activity, Scior et al. [69] described too high expectations concerning
the retrieval of highly active molecules as the ﬁrst pitfall in virtual
screening. The authors state that although the identiﬁcation of highafﬁnity ligands would be desirable, the majority of initial hits are
only weakly active. Similar to initial hits derived from experimental
high-throughput screening, these molecules have to be improved
in further optimization steps.
Intriguingly, while all of the three prospective tools identiﬁed
novel compounds, they only predicted their own virtual hits as
active, but none of the active molecules discovered with the other
two programs. Consequently, none of the tools was a universal
approach to identify most active compounds. To investigate
whether the three programs cover a distinct chemical space, we
analyzed the structural diversity of the nine novel PPARg ligands
with the “Calculate Diversity Metrics” tool implemented in Dis-
covery Studio 4.0 [70]. For the comparison, we selected the 2D
similarity metric ECFP4 and the Tanimoto coefﬁcient (Tc), which
ranks from zero to one. The higher the Tc, the more similar are the
compared compounds. Conversely, the smaller the value, the more
dissimilar the compounds are from a 2D structural point of view.
For the nine active molecules, an average ﬁngerprint similarity of
0.11 was calculated, with a minimum and maximum distance value
of 0.25 and 0.03. The two most similar compounds among the
newly identiﬁed ligands retrieved a Tc of 0.25, thereby suggesting
that all the novel ligands are structurally very distinct from each
other. This study highlights the complementarity of the applied
virtual screening tools with respect to the chemical space the novel
PPARg occupy. Similar observations were also reported by us [71]
and others [32] before.
All molecules of the overall hit list were further investigated
with the external bioactivity proﬁling tools SEA, PASS, and
PharmMapper. SEA predicted only compound 24 to be active,
which could be conﬁrmed in the biological testing. SEA failed to
identify all other eight novel PPARg ligands, however, it correctly
classiﬁed all remaining 20 inactive molecules.
The second 2D similarity-based tool PASS did not predict a
single compound above the activity cut-off. Consequently, it failed
to correctly identify all novel PPARg ligands. However, similar to
SEA, it correctly predicted the inactivity of the remaining 20
compounds.
In accordance with our previous results, the 2D similarity-based
Table 3
Biological screening results of the active molecules.
Compound TR-FRET assay Transactivation assay
% Replacement of ligand ±SD
(10 mM)
% Replacement compared to
pioglitazone (10 mM)
EC50 (mM) % Activation ± SD
(10 mM)
EC50 (mM) Maximum activation compared to 10 mM
pioglitazone (%)
Compound
9
32.6 ± 4.2 48 ± 6 n. d.a 3.5 ± 0.9 n. d. n. d.
Compound
10
54.0 ± 10.6 80 ± 16 2.1 ± 0.3 11.2 ± 8.4 n. d. n. d.
Compound
12
30.9 ± 5.9 46 ± 9 n. d. 8.4 ± 3.4 n. d. n. d.
Compound
15
40.7 ± 5.3 60 ± 8 3.1 ± 0.6 8.3 ± 1.5 n. d. n. d.
Compound
18
30.4 ± 2.9 45 ± 4 n. d. 5.3 ± 4.0 n. d. n. d.
Compound
24
67.1 ± 4.8 99 ± 7 0.6 ± 0.1 20.6 ± 3.9 3.4 ± 0.9 23.7 ± 2.2
Compound
26
58.0 ± 1.9 86 ± 3 2.8 ± 0.4 29.8 ± 6.3 21.7 ± 6.3 41.9 ± 2.7
Compound
29
28.3 ± 9.7 42 ± 14 n. d. 5.3 ± 1.1 n. d. n. d.
Compound
32
51.2 ± 2.4 76 ± 3 5.4 ± 0.7 15.4 ± 4.6 n. d. n. d.
Pioglitazone 67.5 ± 10.6 100 1.6 ± 0.2 100 ± 6.2 0.5 ± 0.1 100
Telmisartan 61.3 ± 3.5 91 ± 5 0.7 ± 0.01 44.8 ± 3.5 4.7 ± 0.3 48.2 ± 3.0
DMSO 4.2 ± 4.8 6 ± 7 n. d. 9.6 ± 2.5 n. d. n. d.
Table 4
Analysis of the method performances.
Program EE (%) OE (%) Acc (%) TP (%) maxTP (%) TN (%) maxTN (%) FP (%) maxFP (%) FN (%) maxFN (%)
LigandScout 30.0 23.1 44.8 10.3 33.3 34.5 50.0 34.5 50.0 20.7 66.7
ROCS 20.0 18.2 44.8 6.9 22.2 37.9 55.0 31.0 45.0 24.1 77.8
GOLD 40.0 36.4 58.6 13.8 44.4 44.8 65.0 24.1 35.0 17.2 55.6
SEA n. d.a 100.0 72.4 3.5 11.1 69.0 100.0 0.0 0.0 27.6 88.9
PASS n. d. 0.0 69.0 0.0 0.0 69.0 100.0 0.0 0.0 31.0 100.0
PharmMapper n. d. 50.0 69.0 3.5 11.1 65.5 95.0 3.5 5.0 27.6 88.9
a n.d. - not determined.
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CYP [40] study, we assumed that this might be explained by the
underlying screening concept: Both programs are machine-Fig. 8. Detailed graphical representation of all method performances. (A) Shows the EE, OE,
the external bioactivity proﬁling tools SEA, PASS, and PharmMapper, because no compoun
composition of the hit lists obtained with every method with respect to TP, TN, FP, and FNlearning tools that calculate the probability of the query molecule
to be active against a speciﬁc target based on the 2D structure of the
query and already known active molecules. As mentioned above,and Acc values retrieved by all applied methods. * The EE could not be determined for
ds were selected for prospective testing based on their predictions. (B) Displays the
rates.
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when we compared them to each other. This suggests that they
possess a very different 2D structure from so far known ligands (a
detailed investigation of the novelty of the scaffolds is provided
below). This could explain why it was very challenging for these
tools to predict these novel scaffolds as active, as no similar known
active compounds are available for comparison. That SEA could
correctly identify at least one of the novel compounds is therefore
remarkable, especially, as the comparison with the most similar
known active compound yielded a Tc of 0.39.
In accordance with our ﬁndings in the CYP study [40], we as-
sume, that these tools do not predict a lot of compounds as active,
but if they do so, it is often correct. This may especially account for
SEA, which, similar to the CYP1A2 results [40], retrieved an OE rate
of 100%. Therefore, we consider it very useful for cherry picking
approaches.
The last external bioactivity proﬁling tool which we applied,
PharmMapper, is largely independent from the structures of
already known active compounds, because it is based on the
interaction patterns of known active compounds rather than their
2D structure. This tool matched two compounds to PPARg phar-
macophore models, of which one was active in the biological
testing. However, similar to the results of the other external
bioactivity proﬁling tools reported here, it did not match many of
the compounds in general.4.2. Novel compounds
To further investigate the novelty of the nine active compounds
with respect to known PPARg ligands, we compared their struc-
tures to that of the known active molecules in the full and partial
agonist dataset that we employed for the theoretical validation. We
decided to include all active molecules in this comparison, because
for seven out of the nine novel ligands their exact biological activity
could not be determined. For the calculation of the similarity, we
applied the “Find similar Molecules” tool implemented in Discov-
ery Studio version 4.0 [70], again using ECFP4 to calculate the ﬁn-
gerprints. This tool also determines the similarity of compounds
with the Tc. In detail, the similarities between compounds 9, 10, 12,
15, 18, 24, 26, 29, and 32 and the most similar compound in the
dataset were calculated as 0.20, 0.28, 0.15, 0.23, 0.34, 0.30, 0.20,
0.22, and 0.15, respectively. The novel molecules are therefore very
dissimilar to the already known active compounds applied during
theoretical validation. In addition, we searched for similar com-
pounds in SciFinder. For all compounds, no reference related to
PPARgwas available. In fact, for seven out of the ninemolecules, not
a single referencewas deposited in SciFinder at all. In a next stepweFig. 9. (A) Comparison of the binding poses of the full agonist pioglitazone (dark gray, PDB-en
Only pioglitazone occupies the side pocket formed by helix H12 and interacts with Tyr473. (
crystallized partial agonist amorfrutin B (gray) in the PPARg crystal structure (PDB-entry 4A4
away from Tyr473. (For interpretation of the references to colour in this ﬁgure legend, theinvestigated, whether molecules with a similarity of80 compared
to the novel ligands identiﬁed in this study were associated with
PPARg before. SciFinder also employs the Tc for determining the
similarity of compounds. However, in this case the values are
normalized to 100. The maximum value that can be retrieved, i.e.
for identical molecules, is therefore 100 instead of one. For com-
pound 15, one derivative (similarity score of 86) was related to
hyperlipidemia and obesity, however, these effects were reported
to be caused by another target [72]. Analogues of compound 18
were further linked to the treatment of hypercholesterolemia [73],
LDL receptor expression [74] (similarity scores of 82), and PPARg
modulation [75] (similarity score of 80). All other compounds were
not associated with PPARg before. These results also highlight the
ability of the applied tools to retrieve structurally novel bioactive
compounds.
To investigate whether the novel PPARg ligands may be false
positive hits that interfere with the assay, they were analyzed with
the PAINS ﬁlter provided by the endocrine disruptome homepage
[76]. However, according to these predictions, the compounds are
not under risk for pan-assay interference. The application of further
ﬁlters is discussed in Section S4 in the supporting information.4.3. Partial agonism
This study did not only evaluate the performances of the applied
tools with respect to the detection of novel PPARg ligands, but the
identiﬁcation of novel partial agonists in particular. In principle,
PPARg has a hydrophobic Y-shaped ligand-binding domain that
consists of 13 a-helices and one b-sheet. The area containing helix
H12 is part of the activation function 2 domain that forms the co-
activator binding-site. Helix H12 is very ﬂexible, and its stabiliza-
tionwith small molecules induces co-activator recruitment and full
activation of the receptor. Hydrogen bondingwith residues on helix
H12 or in close vicinity, especially His323, His449, and Tyr473 were
observed to be a common feature of many full agonists [18].
Partial agonists, however, seem to exert their effects via distinct
protein-ligand interactions: In contrast to full agonists, partial ag-
onists occupy a different region around the b-sheet. In particular,
partial agonists can form hydrogen bonds with Ser342, Arg288,
and, water-mediated, with Glu343 [18]. In addition, extensive hy-
drophobic interactions involving for example Ile281, Ile247, Leu255,
and Gly285 have been observed. Partial agonists therefore do not
stabilize helix H12, but rather helix H3 and the b-sheet. This leads
to altered conformational changes, co-regulator recruitment, and
gene expression proﬁles [18]. Fig. 9A shows the distinct areas of the
PPARg binding pocket the full agonist pioglitazone (PDB-entry
2XKW [77]) and the partial agonist amorfrutin B (PDB-entry 4A4Wtry 2XKW [77]) and the partial agonist amorfrutin B (light gray, PDB-entry 4A4W [64]).
B) The docking poses of compounds 24 (pink) and 26 (blue) in comparison with the co-
W [64]). All compounds are positioned in close proximity to Ser342 and Arg288, but far
reader is referred to the web version of this article.)
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In the cellular assay, for two out of the nine compounds that
proved to bind to the PPARg ligand-binding domain, a biological
activity was observed. These two active compounds activate the
receptor up to 23.7% (p < 0.0001, One way ANOVA and Dunnett's
posthoc test compared to DMSO control) and 41.9% (p< 0.0001, One
way ANOVA and Dunnett's posthoc test compared to DMSO con-
trol), respectively. The EC50 of compound 26 is with 21.7 mM rela-
tively high, however, one has to keep in mind that this compound is
a ﬁrst lead compound that did not undergo further chemical opti-
mization steps so far. Due to their structural novelty, both mole-
cules may represent interesting and promising starting points for
further chemical reﬁnement. Fig. 9B displays the docking poses of
compounds 24 and 26. Both compounds are positioned in close
proximity to Ser342 and Arg288, but far away from Tyr473. These
interaction patterns were described for partial agonists before [18]
and the retrieved docking poses are therefore in accordance with
the biological activity of compounds 24 and 26.
In detail, compound 24 was predicted to form hydrogen bonds
with Arg288, Ser342, Cys285, Gly344, and Leu330. In the majority
of cases, the triﬂuoromethyl-moieties were involved in these in-
teractions. Sulfonamide-oxygen atoms formed the remaining
hydrogen bonds with Arg288 and Leu330. In addition, hydrophobic
contacts with residues Phe226, Leu228, Ile281, Phe287, Ala292,
Leu333, Val339, Ile341, Met348, Leu353, Phe363, and Met364 were
predicted by the docking pose.
For compound 26, docking results suggested hydrogen bonds
with Arg288, Leu340, andewater-mediated - with Ser342, Gly344,
and Ile341. Besides, compound 26 was predicted to be involved in
hydrophobic contacts with Pro227, Leu228, Ile281, Leu333, Val339,
Ile341, Met348, and Leu353.
5. Conclusions
In summary, we applied selected common virtual screening
tools in parallel and independently for the identiﬁcation of novel
PPARg partial agonists. This parallel application allowed us to
directly compare the performances of all tools in a prospective
manner. Similar to our previous studies, where we investigated
other drug target classes, we could observe substantial differences
in the performances of the tools: The three prospective programs
LigandScout, ROCS, and GOLD proved to be very successful in the
identiﬁcation of novel compounds, although we could observe
differences in the numbers of novel ligands they discovered. The
best-performing tool in this study was GOLD, which ranked four
active compoundswithin the top ten of the hit list. Intriguingly, two
of these molecules were ranked at positions one and three, thereby
showing the high suitability of our docking workﬂow for discov-
ering novel PPARg ligands. In contrast, the external bioactivity
proﬁling tools SEA, PASS, and PharmMapper appeared to be very
restrictive. This led to a very limited retrieval of the active com-
pounds. However, also the numbers of false positive hits were
extremely low, making them very valuable tools for cherry picking.
Interestingly, none of the active compounds identiﬁed within this
study was predicted as active by any other of the prospectively
applied programs (LigandScout, ROCS, and GOLD) except the one
that led to their initial identiﬁcation. This ﬁnding suggests that the
programs are highly complementary in terms of the chemical
scaffolds they cover. This is further supported by our similarity
analysis, proving that the novel active compounds have diverse 2D
chemical structures.
In total, nine novel PPARg ligands out of 29 tested compounds
(31.0%) were successfully identiﬁed within this study. The majority
of these compounds is structurally diverse from all so far known
PPARg ligands and may therefore represent promising startingpoints for further chemical optimization. These optimization steps
may not only include the target-related activity, but also pharma-
cokinetic properties, as seven out of the nine compounds did not
show any activity in the cell-based assay. However, these results
make the two compounds 24 and 26, which proved to be partial
agonists in the transactivation assay, interesting lead structures, as
their activity suggests an improved adverse event proﬁle and a
distinct protein-ligand interaction pattern compared to full ago-
nists. Especially compound 26, which showed a sigmoidal
concentration-response curve and a similar binding afﬁnity as the
standard compound pioglitazone in the FRET assay, should be
investigated in further studies.
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